Peter Lichtlen
Director/Miembro de la Junta en LYSOGENE .
Perfil
Peter Lichtlen is the founder of Numab Therapeutics AG, which was founded in 2011.
He is currently an Independent Non-Executive Director at Lysogene SA since 2018.
He is also a Director at Numab Innovation AG, a Member of FMH Swiss Medical Association, and a Member of Swiss Association of Pharmaceutical Professionals, Inc. Dr. Lichtlen previously worked as a Director at Sucampo Acquisitions GmbH.
From 2004 to 2009, he was the Head-Clinical Research & Development at ESBATech, a Novartis Co. GmbH.
He also served as the Senior Medical Officer & VP-European Operations at Sucampo Pharmaceuticals LLC from 2011 to 2014, and at Sucampo GmbH from 2011 to 2018.
Dr. Lichtlen obtained his doctorate degree from the University of Zurich in 1996.
Cargos activos de Peter Lichtlen
| Empresas | Cargo | Inicio |
|---|---|---|
| LYSOGENE | Director/Miembro de la Junta | 01/04/2018 |
| Swiss Association of Pharmaceutical Professionals, Inc. | Corporate Officer/Principal | - |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Fundador | 01/01/2011 |
FMH Swiss Medical Association
 FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland. | Corporate Officer/Principal | - |
Numab Innovation AG
 Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Numab Innovation AG develops multi-specific bio-therapeutics for chronic inflammation and cancer. The private company is based in Wädenswil, Switzerland. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Peter Lichtlen.
| Empresas | Cargo | Fin |
|---|---|---|
Sucampo GmbH
 Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. | Corporate Officer/Principal | 01/02/2018 |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | 01/01/2009 |
Sucampo Acquisitions GmbH
 Sucampo Acquisitions GmbH Financial ConglomeratesFinance Part of Mallinckrodt Plc, Sucampo Acquisitions GmbH is a Swiss company that provides investment services. The company is based in Zug, Switzerland. | Director/Miembro de la Junta | - |
| SUCAMPO PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - |
Formación de Peter Lichtlen.
| University of Zurich | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LYSOGENE | Commercial Services |
| Empresas privadas | 8 |
|---|---|
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Sucampo GmbH
Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. | Health Technology |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
| Swiss Association of Pharmaceutical Professionals, Inc. | |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
FMH Swiss Medical Association
FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland. | Commercial Services |
Numab Innovation AG
Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Numab Innovation AG develops multi-specific bio-therapeutics for chronic inflammation and cancer. The private company is based in Wädenswil, Switzerland. | Commercial Services |
Sucampo Acquisitions GmbH
Sucampo Acquisitions GmbH Financial ConglomeratesFinance Part of Mallinckrodt Plc, Sucampo Acquisitions GmbH is a Swiss company that provides investment services. The company is based in Zug, Switzerland. | Finance |
- Bolsa de valores
- Insiders
- Peter Lichtlen
